News Of The Day
Check Out The Blog For Additional News
Must Watch: HCV Virtual Patient - Cases 1-4 are now available
This activity is a helpful starting point for people who failed treatment, have cirrhosis or want to learn more about current treatment options for various HCV genotypes. Other cases include HCV recurrence after liver transplantation, HCV/HIV co-infection, in addition an explanation of blood tests used in HCV is also featured. This program is amazing folks, enjoy the follow-up questions.
Ledipasvir/sofosbuvir : New Hepatitis C Treatment Needs No Antiviral Boost
Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors
Art of Aging: Testing baby boomers for Hepatitis C
Manufacturing deal wins China cheap supply of GSK's new HIV drug
Genotype 3 Report - Treatment history, 3 Guidelines (EASL, UK, AASLD/IDSA/IAS), prevalence, after disease progression
Bangladesh's Beximco launches copy of Sovaldi
One tablet will cost Tk 600 in Bangladesh, and the total cost of the therapy would be Tk 50,400 for a 12-week course compared to the whooping Tk 67 lakh in developed countries.
Vietnam era veteran carries battle cry of hepatitis C
Blackburn, 62, has hepatitis C virus with stage 4 liver failure. A few weeks ago he was placed on hospice with 3-6 months life expectancy. His diagnosis of hepatitis C didn’t come until Aug. 10, 2014, just six days before his 62nd birthday, when he went to the hospital with severe stomach pain.
Hepatitis C reports only ‘tip of iceberg’
The spread of hepatitis C could be grossly underreported, with fewer than 1 percent of cases reported to federal public health officials, while tens of thousands could be undetected, according to researchers from Massachusetts General Hospital who say the growing opioid crisis is fueling the problem
Most U.S. Hepatitis C Infections May Be Missed: Study
What's behind fatigue, elevated liver enzymes?
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C - EDITORIAL ......"Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function"
Sydney dentist scare: Hygiene breaches put 11,000 people at risk of HIV and hepatitis
Exposure to nature helps quash depression – so enjoy the great outdoors!
Off The Cuff
The bio-imaging artist
Multimedia artist, makes labwork-inspired jewellery — including gold pieces based on structures such as the hepatitis virus.
Holkira Pak : With Provincial Approval Ottawa Doctor Is Expecting To Cure Thousands Of His Patients
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Veterans Administration Ending Hepatitis C Treatments
New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State
FDA Releases Dozens of New Bioequivalence Recommendations, Including for Sovaldi
Physicians should educate pts about medical marijuana to ensure appropriate use and benefits
When Hepatitis C Drapes Us in Shame - Matt Starr
Intradermal HBV Vaccine Appears Safe, Effective for Intramuscular Nonresponders
Hepatitis C Treatment and Injection Drug Users: It Is Time to Separate Fact From Fiction
Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection.
State restrictions for hepatitis C drug may go too far
(Reuters Health) - State-run insurance programs for the poor may be putting up illegal barriers that prevent people with hepatitis C from getting a new treatment, a new study suggests.
FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data
By ED SILVERMAN
File this under ‘Show me the data.’
A pair of public health advocacy organizations has filed a lawsuit against the FDA, claiming the agency failed to release clinical trial data for Gilead Sciences GILD -3.01%’ hepatitis C treatments on a timely basis. And the move is only the latest installment in an ongoing drama in which researchers and patient advocates have tussled with drug makers and regulators over access to such information.
Here’s what happened...
Also see - Public Health Groups Sue FDA For Disclosure of Clinical Trial Data for Costly Hep C Drugs
AbbVie's HOLKIRA™ PAK Now Reimbursed in Ontario
Following the positive CDR recommendation announcement, Ontario is the second province to reimburse HOLKIRA PAK on its public formulary through its Exceptional Access Program (EAP) as of June 29, 20152. In Ontario, HOLKIRA PAK will be covered under the following EAP criteria: for treatment-naïve and treatment-experienced adult patients with GT1 chronic HCV infection, with compensated cirrhosis.
Researchers say method to detect drug resistant hepatitis C virus mutants has been developed
Sisi announces Free Treatment for Military Personnel with Hepatitis C
President Abdel-Fattah El-Sisi has announced that the state will provide free treatment to military personnel infected with hepatitis C, Al-Ahram Arabic reported.
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis
NORCROSS, Ga., June 29, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the screening of the first five patients in its Phase 2 clinical trial with GR-MD-02 in nonalcoholic steatohepatitis (NASH) with cirrhosis. This study, the NASH-CX trial, is a multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase 2 trial to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis
Trans Indie Rocker Isley Reust: I Finally Feel 'Happy to Be the Woman' I Am
But she still had one more hurdle to pass: She was, for all intents and purposes, dying. Her body had mysteriously begun to shut down; by the end of 2011 her immune system and liver had all but failed, while her bladder housed a softball-sized tumor. Months of testing eventually revealed that she had hepatitis C.
Hepatitis C Treatment, the Flu, and the Media
After being on a high for the previous couple of days the flu really got a hold of me last night. The whole family has it, but it is that rare strain of flu known as Man Flu, which always effects men much worse than women. So I had a terrible night's sleep, coughing my lungs up, blocked nose, the whole package. Poor me!
Hepatitis C Treatment and Drug Interactions
Last week in When Hepatitis C Treatment is Hard and Scary, I wrote about side effects of hepatitis C treatment. This week I focus on potential drug interactions. Side effects and drug interactions are connected because if your hepatitis C medication is interacting with another drug or supplement, you may experience some problems.
Weekend Reading - Natural history of hepatitis C: An Updated Look at the Rate of Progression to Cirrhosis and the Incidence of Decompensation
We begin with a commentary titled, "Hepatitis C: 25 Years Old, and Fading," written by William F. Balistreri, MD., recently published over at Medscape. The good doctor writes about a study presented last month at "Digestive Disease Week," which suggested the rate of developing cirrhosis and decompensation in people with HCV is higher than previously thought....
Obstructive sleep apnea is associated with liver disease: a population-based cohort study.
Health officer may declare HIV, hepatitis C epidemic in Clark County
HCV TGIF Rewind - Peak body, Gilead welcome hepatitis report
Welcome to TGIF rewind, a weekly digest of news, research and a look at today's headlines.
Public Health Groups Sue FDA For Disclosure of Clinical Trial Data for Costly Hep C Drugs
June 25, 2015—NEW HAVEN, CT—Treatment Action Group (TAG) and the Global Health Justice Partnership (GHJP) have filed a federal lawsuit to obtain access to the information that Gilead Sciences submitted to the FDA to obtain approval of two new—and extremely expensive—hepatitis C drugs, Sovaldi (sofosbuvir) and Harvoni (sofosvubir/ledipasvir). Hepatitis C affects at least 3 million people in the United States. Sovaldi and Harvoni significantly improve cure rates, but initial pricing was unprecedented: $84,000 and $94,500 for a 12-week course of treatment, respectively.
Viekira Pak - AbbVie hepatitis C cocktail succeeds in late-stage study - 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
- 100 percent SVR(12) rate achieved with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) without ribavirin(1)
Legal Threats to Connecticut Removes HCV Restrictions
California Caps What Patients Pay For Pricey Drugs. Will Other States Follow?
One year after VA scandal, veterans wait to be treated for everything from Hepatitis C to post-traumatic stress
Burman's Specialty Pharmacy shows hepatitis C cure possible while cutting a third of the drug costs
Medication may stop drug and alcohol addiction
VA to outsource care for 180,000 vets with hepatitis C
-The VA is moving to outsource care nationwide for up to 180,000 veterans with hepatitis C.
-The VA spent weeks developing the transition as patient loads surged and funding ran out.
-The sickest veterans generally will get top priority to receive the costly treatment.
Newsweek Story Updated-David Kwiatkowski lab tech who is serving 39-years for infecting people with hepatitis C
Yesterday Newsweek updated their story on David Kwiatkowski, dubbed the "traveling lab technician" who caused the disastrous hepatitis C outbreak at Exeter Hospital in New Hampshire.
China rejects patent linked to Gilead hepatitis C drug
The past year has seen the approval of five interferon-free direct-acting antiviral (DAA) regimens for HCV, including combinations of DAAs and fixed-dose combination pills
Causes of death in people with chronic HBV infection
A study in this month's issue of the Journal of Hepatology investigates the excess risk of death in HBV patients compared with mortality in the general population.
Successes and Challenges on the Road to Cure Hepatitis C
The past year has seen the approval of five interferon-free direct-acting antiviral (DAA) regimens for HCV, including combinations of DAAs and fixed-dose combination pills .
Increased Overdose Deaths Contribute To Fatal Injury Rates
... widespread abuse of the prescription opioid Opana and other counties in Indiana are reporting high rates of Hepatitis C, also linked to intravenous drug use.
Hepatitis Australia- Impact that hepatitis C has on those living with the virus
Produced by Hepatitis Australia, this book is a collection of personal stories
Accessing and Managing Hep C Treatment: Benefits of Working with a Specialty Pharmacy
Watch last month's webinar presented by the American Liver Foundation and learn more about working with a "Specialty Pharmacy" to access and manage hepatitis C treatment.
Hepatitis C: Saving Baby Boomers - Lucinda Porter, RN
Liver function and survival improve after treatment with Viekirax + Exviera regimen
The 3D regimen consists of the HCV protease inhibitor paritaprevir with a ritonavir booster plus the NS5A inhibitor ombitasvir in a once-daily coformulation, taken with the NS5B polymerase inhibitor dasabuvir twice-daily. In Europe the coformulation (Viekirax) and dasabuvir (Exviera) are sold separately; in the US the full regimen is sold together under the brand name Viekira Pak.,,
INVESTIGATION: The Inside Story Of The Money, The Activists, And The Cure For Hepatitis C
HCV NEWS TONIGHT - Patient Friendly Video
The program is presented in an enjoyable TV news format with a look at treating HCV in persons with cirrhosis using lovely Kimberly as a patient case study. I enjoyed the question and answer segment, along with the slide set. Check out who the news anchor is and the field reporter, not to mention the news desk reporter, loving it!
5 Natural Remedies That Won’t Cure Your Hepatitis C
Noninvasive Assessment of Liver Fibrosis
Current Opinion in Gastroenterology, June 17, 2015
NHS accused of delaying access to 'highly tolerable' hepatitis C drugs over cost concerns
Hepatitis C: Learning About HCV Genotype 3 Infection
This summary of articles will offer insight into the following common questions about HCV genotype 3;
Is the rate of fibrosis progression faster when compared with non-3 genotypes? What about a higher grade of steatosis, or higher incidence of hepatocellular carcinoma? Is treating HCV genotype 3 more difficult than treating other genotypes?
Hepatitis C: 25 Years Old, and Fading
Medscape - During 2014, the 25th anniversary of the identification of the hepatitis C virus (HCV), it became clear that a spate of new antiviral drugs and novel treatment strategies heralded a future in which a significant proportion of patients can be cured of ...
Monday Morning Reading: Hepatitis Newsletter and Publication Updates
Good morning folks, welcome to the start of another workweek. Grab a cup of coffee, juice or your favorite beverage on your way over to HCV Advocate to read all about genotypes or sit back and listen to "Webinar: Strategies for Hepatitis C Treatment Access" which aired just last week.
Some fear biotech reaching unsustainable heights - the “Gilead effect”
Pharmacists Need to Weigh Cost–Benefit of Chronic Hepatitis C Drugs
Promoting the Health of Our Hispanic Patients
Rates of cirrhosis and diabetes are higher in Hispanics, and we need to address those problems specifically with such approaches as hepatitis B vaccination, hepatitis C testing and treatment when appropriate, and counseling on physical activity.
Americans, their physicians should take sleep seriously: chest doctors
(Reuters Health) - Getting enough good quality sleep is essential for maintaining health and quality of life, and not getting enough is dangerous to individual health and public safety, according to a new policy statement by the American Thoracic Society (ATS).
Not Just another Hepatitis C Rant
By Lucinda K. Porter, RN
I can rant and rail about insurance and Medicaid denials of coverage for hepatitis C treatment, but I am trying to avoid blood pressure medications. Last week, I listened to an NVHR webinar of experts sharing their experiences trying to obtain prescription coverage for hepatitis C patients. My horror increased as I heard stories about denial after denial. One patient couldn't get a lung transplant until her hep C was treated. Another went through such a horrendous nightmare of denials and appeals that an old anxiety problem kicked back in. There are many stories like this one, and here is a link to one....
June 13 - 12
HCV at a Crossroads:The Pre- or Post-Transplant Treatment Debate
TGIF - A review of this weeks HCV headlines, hot topics and today's news
Effects of delaying Hepatitis C treatment
Latest in testing and treatment of Hepatitis C
The cost of curing hepatitis C
Curing Hard-to-Treat Hepatitis C
Coffee Decreases HCV Advanced Fibrosis Risk
NHS England investing an extra £190 million in new cures for Hepatitis C
Thousands of patients in England with cirrhosis caused by the Hepatitis C Virus will now be able to access new treatment options which can cure the virus and therefore prevent further damage to the liver, including the potential of end stage liver disease or cancer.
Merck May Dent Gilead's Hepatitis C Sales
Merck recently filed a combination therapy for Hepatitis C (grazoprevir and elbasvir) for FDA review, which shows high cure rates for genotypes 1, 4 and 6. This puts it directly on Harvoni’s turf, which is an all oral interferon and ribavarin free therapy offered by Gilead Sciences.
Merck's best hep C strategy is niche marketing, game theory expert figures
To Nalebuff, the thing to do is "protect insurers against a radical rise" in the quantity of patients taking the drugs. His idea? Rather than paying as each patient is diagnosed and treated--and stalling till patients get really sick, to control costs--insurers could pay a flat fee per member.
Sovaldi fight shows we will pay for treatment but not a cure
Inventor of Sofosbuvir Discusses Limited Patient Access to Drug
Hepatitis C's hidden dangers -- a personal perspective: Navin Vij (Opinion)
As a physician, I have often found myself struggling with the concept of why some things happen to certain patients and not to others
Therapeutic regimens for pediatric chronic Hepatitis C
The latest issue of the Alimentary Pharmacology & Therapeutics compares therapeutic regimens for pediatric chronic Hepatitis C.
“Hepatitis C treatment turned me around:” Psychological and Behavioral Transformation Related to Hepatitis C Treatment
Participants described psychological and behavioral transformation over the course of HCV treatment. These included reductions in internalized stigma and shame related to HCV and addiction, increases in HCV disclosure and self-care, reductions in substance use, and new desire to help others who are living with HCV.
Woman Sues Herbal Supplement Seller for Acute Liver Failure
A woman in Indiana is suing Arbonne International, an herbal supplement manufacturer and seller, after one of the company’s regimens allegedly caused her to suffer from acute liver failure, the Allen County Journal Gazette reports.
More women turning to CAM for menopause without medical guidance
The North American Menopause Society (NAMS)
Milk thistle may improve steatohepatitis, capsaicin from chilli peppers may slow fibrosis
People who used silymarin, derived from the milk thistle plant, experienced a resolution of non-alcoholic steatohepatitis (NASH) and a reduction in liver fibrosis in a randomized, placebo-controlled trial, researchers reported at the European
Cost-effectiveness of HCV treatment in early stages of liver disease
A study in the latest issue of Hepatology evaluates the cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.
C-EDGE and C-SURFER trial, Demonstrating High SVR across Broad Range of Hepatitis C Patients announced by MSD
MSD has today announced the first presentation of data from the C-SURFER trial, the first to investigate an all-oral, once-daily, Ribavirin-Free Hepatitis C treatment regimen of grazoprevir (100mg) and elbasvir (50mg) in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus (HCV) genotype 1 and advanced chronic kidney disease (CKD), demonstrating SVR*12 rates of 99 percent.[i] In addition, results from the C-EDGE clinical trial programme were announced, including data sets evaluating treatment-naïve, treatment-experienced and HIV co-infected patients with chronic hepatitis C virus genotypes 1, 4 or 6 Infection, demonstrating SVR 12 rates of 92 to 97 percent.2,3,4 These data were presented at The International Liver CongressTM 2015 – the 50th annual congress of the European Association for the Study of the Liver.
Abbott launches Hepatitis C awareness, diagnosis programme
Goodbye to the Boys on the Bus: How the VA Cured My Hepatitis C
Keeping 'Tract': GI Updates From DDW 2015
Cirrhosis and Hepatitis C - There were a couple of papers related to liver disease that I thought were important.
Hepatitis C: Causes, Symptoms and Treatments
NEJM Knowledge+ Clinical Cases: Treating Hep C
Three in 10 U.S. adults experience drinking problems
New Breakthrough Drugs Will Cost the U.S. Government How Much Money?
Weekend Reading: Talking About HCV Treatment - "Can Hepatitis C Be Cured" or "Am I in remission?"
Check out this CME video presentation
Treatment Can Stop The Progression Of Liver Disease
Hepatitis C Can Be Cured
Cirrhosis Means Risk For Liver Cancer, even after SVR
Fatigue In Most Persons With HCV
Hepatic Fibrosis- Cirrhosis or No Cirrhosis, That Is The Question
Adverse Effects On New HCV Antiviral Therapies
TGIF - Hepatitis News and Headlines
Daklinza® (daclatasvir) - Treatment For Welsh Hepatitis C Patients With Advanced Liver Disease
All Wales Medicines Strategy Group has recommended Daklinza® (daclatasvir) to be used, in combination with other medicinal products, as an option to treat eligible NHS patients with chronic hepatitis C and advanced liver disease.
Changes in Characteristics of HCV Patients in the Last Decade
Journal of Viral Hepatitis, June 5, 2015
In this study of 1348 patients with chronic hepatitis C newly referred to our liver centre, we found as expected patients seen in Era-2 (2011–2012) were older and more likely to have advanced liver disease compared to those seen a decade ago (Era-1, 1998–1999).
New test can identify past viruses with just one drop of blood
The new blood test, which costs as little as $25 (€22), is reportedly able to detect over 1,000 strains of the 206 different types of viruses which are known to infect humans from just one drop of a patient's blood. It works by detecting the existing antibodies within a person's immune system that were created in the past to tackle viruses and have remained in the system in case the virus returns.
Hedge Fund Billionaires Are New Target for Hepatitis C Cure Protests
The New York City home and offices of former hedge fund manager Julian H. Robertson were targeted by protest groups in a series of simultaneous direct actions in early May. Robertson is ranked No. 512 on Forbes' list of "the world's billionaires" with a reported net worth of $3.4 billion. "Robertson is making a killing off of people with Hep C," read one sign.
Experts: Fight Hepatitis C epidemic with more testing, caps for co-pays
WASHINGTON, D.C. ( June 4, 2015 ) — With mounting evidence that many public and private health plans are deliberately rationing care for Americans with the hepatitis C virus ( HCV ), those on the front lines in fighting viral hepatitis and HIV/AIDS today urged lawmakers to overturn state Medicaid and managed care policies that discourage testing, add prior authorization requirements on clinicians, and create significant hurdles for patients to receive new curative treatments — all contributing to only 5% to 6% of individuals with HCV being successfully treated.
HCV Viral Load Testing Not Useful As Measure of New Hepatitis C Drug Effectiveness
Medical Research: What should clinicians and patients take away from your report?
Dr. Kottilil: Clinicians and patients should be aware that frequent monitoring of Hepatitis C RNA levels during therapy may have little utility in guiding treatment duration. Additionally, detectable or low-level quantifiable viremia at end of treatment does not signify treatment failure or necessitate the extension of therapy. However, monitoring Hepatitis C viral levels on treatment for adherence on study medications is important....
Appalachia gripped by hepatitis C epidemic, bracing for HIV
Hepatitis C virus infection, interferon α and lupus; a curious combination
How Much Should a Miracle Drug Cost?
Webinar: Strategies for Hepatitis C Treatment Access
Join us Tuesday June 9 for a webinar covering strategies for attaining access to treatment for patients living with hepatitis C.
VA Loses Outside Provider Claims, Millions of $ Still Unpaid
June Newsletters: The Current State of Hepatitis C Therapy, Pain associated with hepatitis C and More...
Patients Get Extreme to Obtain Hepatitis Drug That's 1% the Cost Outside U.S.
His plan: Dock a cruise ship flying an Indian flag off the coast of Miami. Stock the ship with versions of Sovaldi sold in India for $83,000 less than the U.S. retail price for 12 weeks of treatment. Ferry U.S. patients to the boat and send them home with the potentially life-saving medicines at a huge discount.
FDA Addresses Concerns on Approval of Drugs to Treat Chronic Hepatitis C
Hepatitis C rates in Illinois counties
Dr. E Lebovics: Post- EASL 2015 HCV Interview
Continued use of ribavirin in DAA therapies? Is ribavirin really necessary?
Daclatasvir, Sofosbuvir, and Ribavirin Combination For HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence
What challenges do you think daclatasvir will face should it be approved for use in the US given the current availability of approved DAAs such as ledipasvir/sofosbuvir?
What are the co-factors that increase severity of HCV disease and how should they be managed?
2015 Hepatitis Newsletters
What about last months news?
We have filed it away in our:
2015 - HCV News Digest
HCV News Digest
Email - firstname.lastname@example.org
Where Can I find a specialist to treat HCV?
Find a Specialist In Your Area
Testing, Diagnosis and Treatment
Are you struggling to afford the costs of Hepatitis C treatments? A new program through the HealthWell Foundation may be able to help.
Patient Assistance Programs
Reducing the cost of new hepatitis C drugs
Daclatasvir, Harvoni (ledipasvir/sofosbuvir)/Sovaldi/Viekira Pak.
An index of articles pointing the reader to the current controversy over the high price of Sovaldi, Harvoni (ledipasvir/sofosbuvir) and AbbVie Viekira Pak.
The situation has Medicaid plans and insurers nationwide groping for the right balance. Worldwide patients are unable to afford treatment, while others wait in the wings on coverage
Hepatitis C: Causes, Symptoms and Treatments
The International Liver Congress™ 2015
Indexed by pharmaceutical company
Links to: Interim results from ongoing HCV interferon-free, ribavirin-free clinical trials presented at this months meeting with slide presentations, video highlights and commentary.
Blog - Media Updates
U.S. FDA Approves Gileads Harvoni (Ledipasvir/Sofosbuvir)
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.
Both drugs in Harvoni interfere with the enzymes needed by HCV to multiply. Sofosbuvir is a previously approved HCV drug marketed under the brand name Sovaldi. Harvoni also contains a new drug called ledipasvir.
Mar 3 2015
Gilead's Harvoni gains NICE yes - but won't face funding delay - genotype 1, 4 , but not genotype 3
Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.
Research and Updates
Gilead's Sovaldi (Sofosbuvir) FDA Approved
Sovaldi is approved in HCV genotypes 1 and 4, treatment-naïve adults in combination with PEG-IFN and ribavirin and the first approved interferon-free treatment regimen for people with HCV genotypes 2 and 3. Overall cure rates are at 80%, response rates and treatment duration varies, depending on genotype, viral and host factors.
NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C - The NICE guidance on sofosbuvir recommends its use in combination with ribavirin, with or without peginterferon alfa, as an option for some people with genotypes 1-6 chronic hepatitis C.
Sovaldi (sofosbuvir) - Prescribing And Medication Guides
For detailed information please see Sovaldi (sofosbuvir) - Summary of the basis of approval and highlights from prescribing information and download sofosbuvir FDA review package.
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
Important Safety Information
FDA approves Olysio (simeprevir) in combination with Gilead Sciences' Sovaldi (sofosbuvir)
FDA Approves AbbVie Combo Hepatitis C Treatment
On December 19, 2014, FDA approved VIEKIRA Pak (ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets) for use with or without ribavirin for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.
AbbVie Viekira Pak Homepage
AbbVie Viekira Pak - News, Research and financial support
ABBVIE 'VIEKIRA PAK' - HIGHLIGHTS OF PRESCRIBING INFORMATION
To learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.
Hepatitis C Clinical Trials - FDA Approved And Investigational Drugs
News, Research And Clinical Trials
See **Clinical Trials @ HCV Advocate For Enrollment Information
News and Research
Viekira Pak - (ombitasvir, paritaprevir, ritonavir fixed dose combination tablets copackaged with dasabuvir tablets)
Viekira Pak Prescribing Information
Before FDA Approval
ABT-450/ritonavir/ombitasvir/dasabuvir with or without ribavirin,
r = ritonavir
**Clinical Trials @ HCV Advocate-AbbVie
News and Research
**Clinical Trials @ HCV Advocate-Achillion
News and Research
In January 2014 Boehringer Ingelheim announced the development of deleobuvir would not be continued since recent findings from phase III trials did not suggest sufficient efficacy.
Faldaprevir - On June 20 2014 Boehringer Ingelheim announced it will withdraw all regulatory filings for faldaprevir, which had been granted accelerated assessment by the European Medicines Agency, and will discontinue further development of the protease inhibitor.
**Clinical Trials @ HCV Advocate-Boehringer Ingelheim
News and Research
**Bristol-Myers withdraws FDA NDA for asunaprevir
**Clinical Trials @ HCV Advocate-Bristol-Myers Squibb (BMS)
FDA Approved News and Research
(Sofosbuvir) now Sovaldi
Before FDA Approval
GS-7977 sofosbuvir /GS-5885 ledipasvir,
GS-0938 and Sofosbuvir
Sofosbuvir/Ledipasvir plus GS-9451
Sofosbuvir/Ledipasvir plus GS-9669
GS-7977 now Sofosbuvir and simeprevir (TMC435)
**Clinical Trials @ HCV Advocate-Gilead
News and Research
**Clinical Trials @ HCV Advocate-Idenix
News and Research
Simeprevir now Olysio
Before FDA Approval
Simeprevir now Olysio and Daclatasvir
New - OLYSIO™ (Simeprevir) and Sovaldi (Sofosbuvir)
GS-7977 now Sofosbuvir and simeprevir (TMC435)
Simeprevir (TMC435)-Before FDA Approval
**Clinical Trials @ HCV Advocate-Tibotec / Janssen
News and Research
FDA Approved - Victrelis (Boceprevir)
**Clinical Trials @ HCV Advocate-Merck
News and Research
**ClinicalTrials.gov - Danoprevir
News and Research
**ClinicalTrials.gov - Miravirsen
FDA Approved News and Research
**Vertex to stop selling hepatitis C drug Incivek
..Vertex said it will license an experimental hepatitis C drug called VX-135 to Alios BioPharma..As a reminder (VX-135) is still on partial clinical hold by the FDA in the U.S.
**Clinical Trials @ HCV Advocate-Vertex
Everything You Need To Know Before Starting Treatment
Lucinda K. Porter, RN the author of "Free from Hepatitis C"
new book "Hepatitis C Treatment One Step at a Time" is now available on Amazon
Need To Talk To Someone ?
Patient Advocate Foundation Offers New CareLine for Hepatitis C Patients
Hepatitis C CareLine, providing individualized, sustained assistance to patients diagnosed with Hepatitis C. The CareLine will provide help to patients across the country to resolve healthcare access and insurance issues, at no charge to the patient.